Endpoints and regulatory issues in HIV vaccine clinical trials: Lessons from a workshop

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 1, 2007, Pages 49-60

  Follmann, Dean ^a   Duerr, Ann ^b   Tabet, Stephen ^c   Gilbert, Peter ^c,d   Moodie, Zoe ^d   Fast, Patricia ^e   Cardinali, Massimo ^a,f   Self, Steve ^c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Statistical Center for HIV/AIDS Research and Prevention   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^f Henry Jackson Foundation   (United States)

Author keywords

Clinical trials; Epidemiology; HIV vaccine; Surrogate endpoint

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

AIDS VACCINES; CLINICAL TRIALS; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33845998569     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000247227.22504.ce     Document Type: Conference Paper

References (28)

1. UNAIDS/WHO. AIDS epidemic update. 2003;UNAIDS/03.39E:1.
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.
3. Flynn NM, Forthal DN, Harro CD, et al. The rgp120 HIV Vaccine Study Group. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection. J Infect Dis. 2005;191:654-665.
4. Mascola J, Lewis M, VanCott T, et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol. 2003;77:10348-10356.
5. Letvin N, Mascola J, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 2006;312:1530-1533.
6. Halloran ME, Longini I, Stuchiner C. Design and interpretation of vaccine field studies. Epidemiol Rev. 1999;21:73-88.
7. Schaper C, Fleming T, Self S, et al. Statistical issues in the design of HIV vaccine trials. Annual Review of Public Health. 1995;16:1-22.
8. Longini I, Hudgens M, Halloran M. Estimation of vaccine efficacy for both susceptibility to infection and reduction of infectiousness for prophylactic HIV vaccines with partner augmentation. In: Kaplan E. Brookmeyer R, editors. The Quantitative Evaluation of HIV Prevention Programs. New Haven, CT: Yale University Press; 2002:241-259.
9. Longini I, Datta S, Halloran M. Measuring vaccine efficacy for both susceptibility to infection and reduction of infectiousness for prophylactic HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:440-447.
10. Halloran ME, Haber M, Longini IM, et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol. 1991;133:323-331.
11. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries, efficacy or effectiveness? JAMA. 1996;275:390-397.
12. Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797-804.
13. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
14. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
15. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344:720-725.
16. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate endpoints in phase III trials. J Infect Dis. 2003;188:179-193.
17. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med. 1994;13:1807-1814.
18. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59:531-541.
19. Hudges MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med. 2003;22:2281-2298.
20. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
21. Lawrence C, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11-20.
22. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59:531-541.
23. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemporary Clinical Trials. In press.
24. Halloran ME, Stuchiner CJ. Study designs for dependent happenings. Epidemiology. 1991;2:331-338.
25. Donner A, Klar N. Design and Analysis of Cluster Randomized Trials in Health Research. London: Arnold; 2000.
26. The Gambia Hepatitis Study Group. The Gambia Hepatitis Intervention Study. Cancer Res. 1987;47:5782-5787.
27. Hoff R, Barker LF. Trial objectives and endpoints for measuring the efficacy of HIV. Vaccines Infectious Agents and Disease. 1995;4:95-101.
28. Rida W, Fast P, Hoff R, et al. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immunodefic Syndr Hum Retrovirol. 1997;16:195-203.